Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...

Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...

The US Court of Appeals for the Fifth Circuit is reviving PhRMA's legal attack on Medicare drug price negotiations. On Friday ...

Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...

The US' Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

Apellis has had its European ambitions dashed once again after regulators reaffirmed their decision to not recommend the ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...

Novo Nordisk has ended one of the multiple trials testing the lead oral drug from its $1.1 billion Forma Therapeutics buyout, ...

Sanofi released new Phase 3 data for its BTK inhibitor tolebrutinib in non-relapsing secondary progressive multiple sclerosis ...

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.